J&J Unit Loses In Ark.'s Risperdal Marketing Suit

Law360, New York (April 10, 2012, 9:39 PM EDT) -- A jury sided against a Johnson & Johnson subsidiary Tuesday in Arkansas' suit claiming it illegally promoted the antipsychotic drug Risperdal to doctors for unnecessary medical conditions at a cost to the state, opening the company up to potentially huge liability.

The suit, filed in November 2007 in state court, also alleged that Janssen Pharmaceuticals Inc. misrepresented the risks of the medication to patients. The state seeks to recover the money it paid to provide Risperdal to patients through Medicaid and other programs, as well as...
To view the full article, register now.